Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.58 |
| ▸ | MTOR | P42345 | 11/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.58 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.58 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.58 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.58 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.58 |
| ▸ | PRF1 | P14222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452518 | 0.92 | PIK3CA (0.59) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL454365 | 0.90 | PIK3CA (0.53) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL454735 | 0.89 | PIK3CG (0.56) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL15975806 | 0.89 | PIK3CA (0.56) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2551599 | 0.88 | PIK3CA (0.51) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL454938 | 0.87 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL452267 | 0.86 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL451324 | 0.86 | PIK3CA (0.57) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL456401 | 0.86 | PIK3CA (0.59) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL451311 | 0.85 | PIK3CA (0.53) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | claimed |
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| WO-2011121317-A9 | IMIDAZOTHIADIAZOLES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-03-15 | — | — | WO | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011121317-A1 | IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | PIK3CA 1/4885MTOR 39/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.